Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
NUVL
NUVL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NUVL News
Nuvalent to Speak at Biotech Summit 2026
Feb 05 2026
PRnewswire
Nuvalent to Speak at Biotech Summit 2026
Feb 05 2026
Newsfilter
Nuvalent Submits NDA for Zidesamtinib, Targeting Approval by September 2026
Jan 12 2026
PRnewswire
Nuvalent Submits NDA for Zidesamtinib, Targeting 2026 U.S. Launch
Jan 12 2026
Newsfilter
Royalty Pharma Acquires Evrysdi Royalty for $240 Million Upfront
Dec 31 2025
Benzinga
Nuvalent CEO James Porter to Present at 2026 J.P. Morgan Healthcare Conference
Dec 22 2025
Newsfilter
Nuvalent CEO to Present at J.P. Morgan Healthcare Conference on January 13, 2026
Dec 22 2025
PRnewswire
Nuvalent Appoints Ron Squarer to Board of Directors to Enhance Oncology Strategy
Dec 10 2025
PRnewswire
Nuvalent Appoints Ron Squarer to Board, Enhancing Oncology Expertise
Dec 10 2025
Newsfilter
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nov 26 2025
PRnewswire
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nov 24 2025
PRnewswire
Nuvalent Files NDA for Zidesamtinib, Targeting FDA Approval by September 2026
Nov 24 2025
Newsfilter
FDA Approves Nuvalent's New Drug Application for Zidesamtinib in ROS1-Positive Non-Small Cell Lung Cancer
Nov 20 2025
NASDAQ.COM
FDA Accepts Nuvalent's NDA for Zidesamtinib in ROS1-Positive NSCLC
Nov 20 2025
NASDAQ.COM
Nuvalent's Zidesamtinib Undergoes FDA Review for ROS1-Positive Lung Cancer
Nov 19 2025
Yahoo Finance
Nuvalent Reports FDA Acceptance of New Drug Application for Zidesamtinib to Treat TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nov 19 2025
Newsfilter
Show More News
